Immune design corp. (IMDZ)
Income statement / Quarterly
Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13Jun'13
Revenues:
Total revenues

-

462

755

-

-

516

729

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaborative revenue

-

-

-

496

-

-

-

5,204

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Licensing revenue

-

-

-

-

-

-

-

-

-

7,000

-

-

-

3,500

-

-

-

3,500

1,000

-

13

514

Collaborative revenue

-

-

-

-

-

-

-

-

-

780

400

1,856

-

329

1,761

1,849

-

0

0

0

-

0

Product sales

-

-

-

7

-

-

-

261

-

426

733

7

921

824

19

89

748

44

64

25

116

368

Total revenues

-

-

-

503

-

-

-

5,465

-

8,206

1,133

1,863

1,139

4,653

1,780

1,938

1,800

3,544

1,064

25

129

882

Operating expenses:
Cost of product sales

-

32

-

-

-

16

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of product sales

-

-

140

7

-

-

18

37

-

72

253

22

353

298

44

79

575

31

18

14

70

250

Research and development

9,836

11,268

11,000

10,311

8,523

10,246

10,863

14,038

12,005

11,173

11,386

10,570

8,878

8,263

8,483

7,463

8,797

5,988

3,883

4,078

2,920

3,356

General and administrative

3,593

3,802

4,006

3,995

4,321

3,909

3,888

4,135

4,443

9,554

3,948

3,914

4,048

3,506

3,778

3,802

5,549

4,082

1,850

1,446

1,132

914

Total operating expenses

14,685

15,102

15,146

14,313

12,857

14,171

14,769

18,210

16,582

20,799

15,587

14,506

13,279

12,067

12,305

11,344

14,921

10,101

5,751

5,538

4,122

4,520

Loss from operations

-14,209

-14,640

-14,391

-13,810

-12,372

-13,655

-14,040

-12,745

-14,524

-12,593

-14,454

-12,643

-12,140

-7,414

-10,525

-9,406

-13,121

-6,557

-4,687

-5,513

-3,993

-3,638

Interest and other income

608

591

583

510

392

239

194

125

78

150

107

349

25

7

8

0

1

2

0

1

-1

4

Change in fair value of convertible preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

127

1,439

2,711

0

0

Net loss

-13,601

-14,049

-13,808

-13,300

-11,980

-13,416

-13,846

-12,620

-14,446

-12,443

-14,347

-12,294

-12,115

-7,407

-10,517

-9,406

-13,120

-6,682

-6,126

-8,223

-3,994

-3,634

Unrealized gain (loss) on investments

17

16

32

-18

-35

29

4

-23

-31

-23

10

20

0

0

0

0

-

-

-

-

-

-

Comprehensive loss

-13,584

-14,033

-13,776

-13,318

-12,015

-13,387

-13,842

-12,643

-14,477

-12,466

-14,337

-12,274

-12,115

-7,407

-10,517

-9,406

-

-

-

-

-

-

Basic and diluted net loss per share (in dollars per share)

-0.28

-0.29

-0.29

-0.28

-0.19

-0.52

-0.54

-0.50

-0.55

-0.60

-0.71

-0.61

-0.59

-0.37

-0.54

-0.56

34.81

-0.55

-16.57

-22.25

-10.81

-9.84

Weighted-average shares used to compute basic and diluted net loss per share (in shares)

48,168

48,164

48,125

48,122

41,856

25,620

25,567

25,463

25,441

20,803

20,155

20,153

20,191

20,131

19,356

16,944

17,110

12,128

369

369

369

369